Praxis Precision Medicines
PRAX
68 hedge funds and large institutions have $1.19B invested in Praxis Precision Medicines in 2021 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 25 increasing their positions, 14 reducing their positions, and 12 closing their positions.
79% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 14
0.02% more ownership
Funds ownership: 6.31% → 6.33% (+0.02%)
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
1% less funds holding
Funds holding: 69 → 68 (-1)
40% less capital invested
Capital invested by funds: $1.96B → $1.19B (-$776M)
67% less funds holding in top 10
Funds holding in top 10: 6 → 2 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$32.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$26.5M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$9.26M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$7.87M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$3.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$19.3M |
| 2 |
O
OrbiMed
New York
|
-$14.1M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$13.8M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$6.4M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$5.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DKCM
76
Davidson Kempner Capital Management
New York
| – | -$548K | -667 | Closed |
|
|
CCM
77
CAAS Capital Management
New York
| – | -$275K | -333 | Closed |
|
|
IC
78
Ikarian Capital
Dallas,
Texas
| – | -$275K | -333 | Closed |
|
79
VOYA Investment Management
Atlanta,
Georgia
| – | -$218K | -264 | Closed |
|
80
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | +$711 | +1 | New |
|
PRAX Hedge Fund Activity: Q1 2021 in Review
68 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q1 2021, worth a combined $1.19B — down 40% from $1.96B a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of PRAX and 11 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 25 added.
The largest buyer was Fidelity Investments, adding an estimated $32.4M. The largest seller was Deerfield Management, exiting entirely with an estimated $19.3M sold.
- 68 institutional investors held Praxis Precision Medicines (PRAX) as of Q1 2021, down from 69 in Q4 2020.
- Funds reported $1.19B of Praxis Precision Medicines stock for Q1 2021, down 40% quarter-over-quarter.
- 11 funds opened new Praxis Precision Medicines positions in Q1 2021 and 12 closed out, a net change of -1 holder.
- The largest Praxis Precision Medicines buyer in Q1 2021 was Fidelity Investments, an estimated $32.4M added.
- The largest Praxis Precision Medicines seller in Q1 2021 was Deerfield Management, an estimated $19.3M sold.
Based on aggregated 13F filings for Q1 2021.